Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.20.4
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 12 Months Ended
Jan. 31, 2021
Aug. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Jan. 31, 2018
Commitments and Contingencies (Details) [Line Items]          
Upfront payments         $ 25,000
Research and development expense     $ 10,000    
Granted period     5 years    
Product candidates     $ 71,000 $ 234,000  
Prepaid expense     85,000    
Patents [Member]          
Commitments and Contingencies (Details) [Line Items]          
Related patents costs     $ 0 74,000  
Net revenue, percentage     50.00%    
Subsequent Event [Member]          
Commitments and Contingencies (Details) [Line Items]          
Total Payments $ 600,000        
AF Chemicals [Member]          
Commitments and Contingencies (Details) [Line Items]          
Commitments and contingencies, description     the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development in the accompanying consolidated statements of operations.    
Milestone extension paid     $ 25,000    
LP-100 [Member] | AF Chemicals [Member]          
Commitments and Contingencies (Details) [Line Items]          
Expenses     $ 30,000 30,000  
EU Grant [Member]          
Commitments and Contingencies (Details) [Line Items]          
Research and development expenses percentage     50.00%    
Patheon API Services [Member]          
Commitments and Contingencies (Details) [Line Items]          
Manufacturing agreement, description     The Company paid approximately $203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000 was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable and accrued expenses on the Company’s consolidated balance sheet for the period ended December 31, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.    
Southwest Research Institute [Member]          
Commitments and Contingencies (Details) [Line Items]          
Research and development expense     $ 82,000 $ 13,000  
Prepaid expense     97,000    
Operating Lease [Member]          
Commitments and Contingencies (Details) [Line Items]          
Lease term, description   the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.      
AF Chemicals [Member] | LP-184 [Member]          
Commitments and Contingencies (Details) [Line Items]          
Annual fees     30,000    
BioNumerik Pharmaceutical [Member]          
Commitments and Contingencies (Details) [Line Items]          
Upfront payments     $ 25,000    
Commitments and contingencies, description     In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.    
Amounts payable     $ 11,000